Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT01829399Phase 4Completed
Phase 4, randomised, double-blind trial of bupivacaine hydrochloride 0.75% injection (2 arms), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Time in Minutes That Tq Remained Inflated up to 60 minutes. Started Apr 2013; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT01829399.